Skip to main content
AGIO
NASDAQ Life Sciences

FDA Pushes Mitapivat Sickle Cell Decision to February 2027 After Major Amendment

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$37.25
Mkt Cap
$2.223B
52W Low
$22.24
52W High
$46
52W Position info
67% above low
Off High info
19% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

AGIO sits 67% above its 52-week low of $22.24.

Summary

The FDA moved the PDUFA goal date for mitapivat in sickle cell disease from November 1, 2026 to February 1, 2027, a three-month delay. The trigger was Agios' October 19 response to an October 9 FDA request for information on whether a REMS is needed; the agency classified that response as a major amendment on October 28. Agios says the updated safety data through October 9 showed no cases of hepatocellular injury with the pattern seen in its thalassemia trials, and that the benefit-risk profile is unchanged. The delay matters because sickle cell is the largest indication Agios has pursued for mitapivat and management calls it a significant growth driver; the company says it is launch-ready and in labeling discussions, including potential REMS elements. The stock reaction will hinge on whether investors read this as a routine review extension or as rising REMS risk, given the boxed liver warning already on the thalassemia label. The February 1, 2027 goal date is the next hard milestone.

At the time of this announcement, AGIO was trading at $37.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $22.24 to $46.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

AGIO - Latest Insights

AGIO
Nov 05, 2026, 9:38 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.75
Real-time Price: $31.59 info
Change: +$2.84 (+10%) info
Market Cap: $1.889B info
AGIO
Nov 05, 2026, 6:33 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.90
Real-time Price: $31.59 info
Change: -$0.310 (-0.97%) info
Market Cap: $1.889B info
AGIO
Nov 05, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $31.90
Real-time Price: $31.59 info
Change: -$0.310 (-0.97%) info
Market Cap: $1.889B info
AGIO
Jul 30, 2026, 9:56 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.52
Real-time Price: $31.59 info
Change: +$0.070 (+0.22%) info
Market Cap: $1.889B info
AGIO
Jul 30, 2026, 6:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.25
Real-time Price: $31.59 info
Change: -$4.66 (-13%) info
Market Cap: $1.889B info